An immunotherapy drug embedded in a slow-release hydrogel invented at Rice University in collaboration with the University of Texas Health Science Center at Houston (UTHealth) appears to be highly effective at killing cancer cells.
STINGel combines a new class of immunotherapy drugs called stimulator of interferon gene (STING) agonists with an injectable hydrogel that releases the drug in a steady dose to activate the immune system to kill cancer cells. It was developed by the Rice lab of chemist and bioengineer Jeffrey Hartgerink and Rice alum Simon Young, an assistant professor of oral and maxillofacial surgery at UTHealth.
In clinical trials, immunotherapy drugs have demonstrated strong cancer-fighting abilities. Research has also found that the drugs are flushed quickly from the body, and current trials require multiple injections.
The new research, which is detailed in Biomaterials, showed that slow-release peptide gels could continuously deliver immunotherapy drugs to tumor sites for long periods of time.
Hartgerink is a pioneer in the development of self-assembling multidomain peptide (MDP) hydrogels, which mimic the body’s extracellular matrix to encourage the growth of cells and vascular systems for tissue repair. The hydrogel is injected as a liquid, turns semisolid inside the body and slowly degrades over time.
The hydrogel in the new study is also welcoming to cells, but when the invaders are cancer cells, they’re in for trouble. Immunotherapy drugs known as cyclic dinucleotides (CDNs) await them inside the gel.
Hartgerink, a professor of chemistry and bioengineering, said the concentration of CDN in the hydrogel is important.
“The normal approach to CDN delivery is simple injection, but this leads to very rapid diffusion of the drug throughout the body and reduces its concentration at the site of the tumor to very low levels,” he said. “Using the same amount of CDN, the STINGel approach allows the concentration of CDN near the tumor to remain much higher for long periods of time.”
STINGel was studied both in lab cultures and in vivo. For the in vivo portion, six groups of 10 rodents each were treated with CDN alone, control collagens alone or with CDN, MDP alone or STINGel (CDN plus MDP). Only one in 10 CDN or collagen plus CDN animals survived 105 days, but six of 10 animals treated with STINGel survived. These also proved resistant to further implantation of cancer cells, meaning their immune systems were trained to successfully identify and destroy both the existing cancer and future occurrence of that cancer, Hartgerink said.
The lab tested more common hydrogels but found that they were unable to provide the same controlled release and also failed to provide an additional benefit over CDN treatment seen in clinical trials. “The MDP hydrogel provides a unique environment for the release of CDN that other gels just can’t match,” Hartgerink said.
“The CDN we used in this study is currently in clinical trials,” he said. “We think that our STINGel approach has the potential to significantly broaden the scope of this powerful immunotherapy drug to a larger range of resistant cancers.”
Rice graduate student David Leach is lead author of the STINGel study. Co-authors are Rice graduate student Tania Lopez-Silva; research associate Neeraja Dharmaraj and resident Stacey Piotrowski; Yu Lei, an assistant professor of dentistry and otolaryngology at the University of Michigan, and Andrew Sikora, vice chair for research and co-director of the head and neck cancer program at Baylor College of Medicine.
The research was supported by the National Institutes of Health, the Oral and Maxillofacial Surgery Foundation, the Welch Foundation, the National Science Foundation and the Mexican National Council for Science and Technology.
@hawkeyejp27 We appreciate the RT ^SF
@TimAllenMDJD We appreciate the RT ^SF
@onco_cardiology Thanks for sharing ^SF
Women need #cancer screening exams starting at age 21. What to know: https://t.co/bRQ1nsFCyM #endcancer https://t.co/g019IWFKeo
Acting secretary visits Texas facilities looking for best practices that could be implemented nationwide https://t.co/0G07eEchwf via #VAntagePoint
Today’s #VeteranOfTheDay is Army Veteran Joseph Stephen Acsai. https://t.co/JoNIds6nqW…ph-stephen-acsai/
Bowling alley is hidden gem of Brockton VA campus https://t.co/J5DBcAYw65 via @enterprisenews
Huntington's and other neurological diseases multitude of molecular changes have helped scientists create a new approach to find what is driving these diseases. https://t.co/lUptEn0mYt
Our expert Dr. Christopher Logothetis shares what makes our Prostate #CancerMoonshot unique: https://t.co/5gpw04T1Gm #CancerMoonshot #endcancer https://t.co/frhL4VfmO9
First-gen students learn how to build rockets, connect with peers and fulfill college dreams at #RiceUniversity's Young Owls Leadership Camp. https://t.co/otf6W9r32K https://t.co/OQst25jY3E
30,000: # of outside pathology reports we review annually 25%: percentage of pathology findings that change from the initial diagnosis See how our pathologists changes lives: https://t.co/F5HBkCgjJi #endcancer
Looking to reduce the risk of heart disease? You might want to think about taking a trip down the aisle. https://t.co/AddjPUl5WX
After a two-story fall outside her home, Meena suffered a spinal cord injury that left her paralyzed from the pelvis down. But she took this life challenge as an opportunity to rewrite her story. Watch how she is living a new normal: https://t.co/twBxH9uykC. https://t.co/w0wxYkYzQE
.@BCM_SportsMed Dr. Mark Adickes talks about life after NFL with @CarliLloyd and how that experience shapes how he treats his patients. https://t.co/AiYGAdNlnN
RT @RiceUNews: Today #SaudiArabia puts an end to its ban on women driving, opening the way for millions of new drivers to navigate a countr…